Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Increase in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 268,144 shares, an increase of 88.7% from the June 30th total of 142,122 shares. Based on an average daily volume of 1,758,154 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are sold short.

Wall Street Analyst Weigh In

BAYRY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

BAYRY stock opened at $13.97 on Friday. Bayer Aktiengesellschaft has a twelve month low of $7.19 and a twelve month high of $15.23. The firm has a market cap of $54.90 billion, a price-to-earnings ratio of -21.83, a PEG ratio of 4.38 and a beta of 0.55. The business’s fifty day simple moving average is $12.26 and its two-hundred day simple moving average is $12.05. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion during the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Analysts predict that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.